Vitamin D, Sunlight, and the Natural History of Prostate Cancer

Vitamin D

Volumn 2, Issue , 2005, Pages 1599-1615

  Schwartz, Gary G ^a   Chen, Tai C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646891710     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50094-2     Document Type: Chapter

References (128)

1. Schwartz GG, Hulka BS Is vitamin D deficiency a risk factor for prostate cancer (hypothesis)?. Anticancer Res 1990, 11:1307-1311.
2. Schwartz GG Prostate cancer and vitamin D: From concept to clinic. A 10-year update. Vitamin D Endocrine System 2000, 445-452. University of California Press. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
3. Holick MF, Photobiology of vitamin D, In: Feldman D, Glorieux FH, Pike JW, Vitamin D, 1st ed, Academic Press: San Diego, CA: 33-39.
4. Holick MF The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990, 120(Suppl 11):1464-1469.
5. 3-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
6. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomark Prev 1998, 7:391-395.
7. 3 and its analogs on growth control and tumorigenesis. Front Biosc 2001, 6:D820-D848.
8. Omdahl JL, Morris HA Hydroxylase enzymes of the vitamin D pathway: Expression, function, and regulation. Annu Rev Nutr May 2002, 22:139-166.
9. Vieth R Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.
10. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Thomsen H, Charles P, Eriksen EF Commonly recomended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000, 247:260-268.
11. American Cancer Society, Cancer Facts & Figures 2003.
12. Cancer mortality statistics in the world 1989, University of Nagoya Press, Japan, 1950. M. Kurihara, K. Aoki, S. Hismamichi (Eds.).
13. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD The frequency of carcinoma and intraepithelial neoplasia of the prostate in young adult patients. J Urol 1993, 150:379-385.
14. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate in seven areas. Int J Cancer 1977, 20:680-688.
15. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P Prevalence of latent prostate carcinoma in two U.S. populations. Natl Cancer Inst 1980, 65:311-316.
16. Yatani R, Chigusa I, Akazaki K, Stermmerman G, Welsh R, Correa P Geographic pathology of latent prostate carcinoma. Int J Cancer 1984, 29:611-616.
17. Haenzel W, Kurihara M Studies of Japanese migrants: I. Mortality from cancers and other diseases among Japanese in the United States. J Natl Cancer Inst 1968, 40:344-360.
18. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 2000, 7:254-257.
19. Russell RM The aging process as a modifier of metabolism. Am J Clin Nutr 2000, 72:529S-532S.
20. MacLaughlin J, Holick MF Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985, 76:1536-1538.
21. Lips P Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
22. Passeri G, Pini G, Triano L, Vescovini R, Sansoni P, Passeri M, Guerresi P, Delsignore R, Pedrazzoni M, Franceschi C Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab 2003, 88:5109-5115.
23. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 1991, 127:536-538.
24. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J Evidence for alteration of the vitamin D endocrine system in blacks. J Clin Invest 1985, 76:470-473.
25. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Doughertly C, Gunter EW, Bowman BA Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey. Am J Clin Nutr 1988-1994, 76:187-192.
26. Nakamura K, Nashimoto M, Hori Y, Muto K, Yamamoto M Serum 25-hydroxyvitamin D levels in active women of middle and advanced age in a rural community in Japan. Nutrition 1999, 15:870-873.
27. Nakamura K, Nashimoto M, Hori Y, Yamamoto M Serum 25-hydroxyvitamin D concentrations and related dietary factors in peri- and postmenopausal Japanese women. Am J Clin Nutr 2000, 71:1161-1165.
28. Nakamura K, Nashimoto M, Okuda Y, Ota T, Yamamoto M Fish as a major source of vitamin D in the Japanese diet. Nutrition 2002, 18:415-416.
29. Takeuchi A, Okano T, Ayame M, Yoshikawa H, Teroaka S, Murakami Y, Kobayashi T High-performance liquid chromatographic determination of vitamin D3 in fish liver oils and eel body oils. J Nutr Sci Vitaminol 1984, 30:421-430.
30. Henderson JB, Dunnigan MG, McIntosh WB, Abdul Motall AA, Gettinby G, Glekin BM The importance of limited exposure to ultraviolet radiation and dietary factors in the etiology of Asian rickets: A risk-factor model. Q J Med 1987, 63:413-425.
31. Stephens WP, Klimiuk PS, Warrington S, Taylor IL, Berry JL, Mawer EB Observations on the natural history of vitamin D deficiency among Asian immigrants. Q J Med 1982, 202:171-188.
32. Abrams SA Nutritional rickets: an old disease returns. Nutr Rev 2002, 60:111-115.
33. Heaney RP Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutrition 2003, 78:912-919.
34. 3] binding sites in male sex organs of the mouse: An autoradiographic study. J Histochem Cytochem 1989, 37:1083-1086.
35. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P The human prostatic carcinoma cell line LNCap expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992, 52(3):515-520.
36. Meade MS, Earickson RJ Medical Geography 2000, Guilford Press, New York.
37. Hanchette CL, Schwartz GG Geographic patterns of prostate cancer mortality. Evidence for a protective effect, of ultraviolet radiation. Cancer 1992, 70:2861-2869.
38. Kafadar K Geographic patterns of prostate cancer mortality. Spatial smoothing and the need for adjustment. Annals of Epidemiology 1998.
39. Grant WB An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
40. Di Silverio F, La Pera G, Tenaglia R Age-adjusted mortality rate and regional distribution for prostatic carcinoma in Italy between 1969 and 1978. Prostate 1982, 3:631-636.
41. Vercelli M, Quaglia A, Marani E, Parodi S Prostate cancer incidence and mortality trends among elderly and adult Europeans. Critical Reviews in Oncology/Hematology 2000, 35:133-144.
42. Schwartz GG Vitamin D and the Big Three: Cancers of the Colon, Breast, and Prostate. Biological Effects of Light 2002, 255-265. Kluwer, Amsterdam. M.F. Holick (Ed.).
43. Braun MM, Helsouer KH, Hollis BW, Comstock GW Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995, 6:235-239.
44. Nomura AMY, Stemmerman GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998, 9:525.
45. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998, 7:385-390.
46. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
47. 3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J Immunol 1993, 150:3487-3495.
48. 3 in normal human keratinocytes. J Cell Physiol 1998, 174:1-8.
49. Vieth R Enzyme kinetic hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25-hydroxyvitamin D in Scandinavian countries [letter]. Int J Cancer 2004, 111:468.
50. Mawer EB, Walls J, Howell A, Daview M, Ratcliffe WA, Bundred NJ Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 1997, 82:118-122.
51. Niv Y, Sperber AD, Figer A, Igael D, Shany S, Fraser G, Schwartz B In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma. Cancer 1999, 86:391-397.
52. 2D in relation to prostate cancer: A hypothesis. Cancer Causes Control 1998, 9:467-472.
53. Chan JM, Giovannucci E, Andersson S-O, Yeun J, Adami H-O, Wolk A Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer. Cancer Causes Control 1998, 9:559-566.
54. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001, 74:549-554.
55. Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA Animal products, calcium, and protein and prostate cancer risk in the Netherlands, Cohort Study. Br J Cancer 1999, 80:1107-1113.
56. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA Calcium intake and prostate cancer risk in a long-term aging study: The Baltimore Longitudinal Study of Aging. Urology 2002, 60:1118-1123.
57. Vieth R Dairy products, calcium, and prostate cancer risk in the Physicians' Study [letter]. Am J Clin Nutr 2002, 76:490-491.
58. Bell NH, Shaw S, Turner RT Evidence that calcium modulates circulating 25-hydroxyvitamin D in man. J Bone Miner Res 1987, 2:211-214.
59. Konety BR, Schwartz GG, Acierno JS, Becich MJ, Getzenberg RH The role of Vitamin D in normal prostatic growth and development. Cell Growth & Differentiation 1996, 7:1563-1570.
60. Christako S, Dhawan P, Liu Y, Peng X, Porta A New insights into the mechanisms of vitamin D action. J Cell Biochem 2003, 88:695-705.
61. 3 are mediated exclusively through the genomic signaling pathway. Endocrinol 1996, 137:1554-1561.
62. Ntais C, Polycarpou A, Ionnidis PA Vitamin D receptor gene polymorphisms and risk of prostate cancer. Cancer Epidem Biomark Prev 2003, 12:1395-1402.
63. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA Association of prostate cancer with vitamin D receptor genet polymorphism. Cancer Res 1996, 56:4108-4110.
64. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W Vitamin D receptor polymorphisms as markers in prostate cancer. Human Genet 1999, 105:281-287.
65. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001, 48:543-549.
66. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Human Genet 2002, 47:413-418.
67. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int 2002, 68:226-231.
68. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto KL, Wang W, Haile RW Association of prostate cancer with vitamin D, receptor haplotypes in African Americans. Cancer Res 1998, 58:1620-1623.
69. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000, 60:305-308.
70. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomark Prev 2003, 12:23-27.
71. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Goetzee GA Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997, 89:166-170.
72. Kibel AS, Issacs SD, Isaacs WB, Bova GS Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998, 160:1405-1409.
73. Furuya Y, Akakura K, Masai M, Ito H Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. Endocr J 1999, 46:467-470.
74. Watanabe M, Fukutome K, Murata M, Uemura H, Kubota Y, Kawamura J, Yatani R Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res 1999, 19:4511-4514.
75. Blazer DG, Umbach DM, Bostick RM, Taylor JA Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinogen 2000, 27:18-23.
76. Chokklingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF, Hsing AW Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based casecontrol study in China. Cancer Res 2001, 61:4333-4336.
77. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, Vutuc C, Micksche M Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002, 51:30-34.
78. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Koike H, Nakazato H, Okugi H, Hasumi M, Fukabori Y, Kurokawa K, Yamanaka H Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urology 2003, 10:261-266.
79. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003, 88:928-932.
80. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Adao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000, 58:1620-1623.
81. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC Prostate cancer risk: associations with ultraviolet radiation, tyrosinase, and melanocortin-1 receptor genotypes. Br J Cancer 2001, 85:1504-1509.
82. Barger-Lux MJ, Heaney RP Effects of above-average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. J Clin Endocrinol Metab 2002, 87:4952-4956.
83. Fitzpatrick TB The validity and practicality of sunreactive skin types I through VI. Arch Dermatol 1988, 124:869-871.
84. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC Susceptibility to prostate cancer: Studies on interactions between UVR exposure and skin type. Carcinogenesis 2003, 24:711-717.
85. Arnot B The Prostate Cancer Protection Plan: The Foods, Supplements and Drugs that Could Save Your Life 2000, Little, Brown & Co., Boston, MA.
86. Walsh PC, Worthington JF The Prostate: A Guide for Men 1995, Johns Hopkins University Press, Baltimore, MD.
87. Freedman DM, Dosemeci M, McGlynn K Sunlight and mortality from breast, ovarian, colon, prostate, and nonmelanoma skin cancer: A composite death certificate based case-control study. Occup Environ Med 2002, 59:257-262.
88. Schwartz GG Multiple sclerosis and prostate cancer: What do their similar geographies suggest?. Neuroepidemiol 1992, 11:244-254.
89. 3 from sunlight may improve the prognosis of breast, colon, and prostate cancer. Cancer Causes Control 2004, 15:149-158.
90. Maon J, Dahlback A, Henricksen T, Magnus K Biological amplification factor for sunlight-induced nonmelanoma skin cancer at high latitudes. Cancer Res 1989, 49:5207-5212.
91. John EM, Dreon DM, Koo J, Schwartz GG Residential sunlight exposure is associated with a decreased risk of prostate cancer. Journal of Steroid Biochemistry & Molecular Biology 2004, 89-90:549-552.
92. Kristal AR, Cohen JH, Qu P, Stanford JL Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidem Biomar 2002, 11:719-725.
93. Heaney RP, Daview KM, Chen TC, Holick MF, Barger-Lux MJ Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
94. Poskitt EM, Cole TJ, Lawson DE Diet, sunlight, and 25-hydroxy vitamin D in healthy children and adults. Br Med J 1979, 1:221-223.
95. Ewings P, Bowie C A case-control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 1996, 74:661-666.
96. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A Fatty fish consumption and risk of prostate cancer. Lancet 2001, 357:1764-1766.
97. Terry PD, Rohan TE, Wolk A Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and other hormone-related cancers: A review of the epidemiologic evidence. Am J Clin Nutr 2003, 77:532-543.
98. 3 in several species of fishes. J Nutr Sci Vitaminol 1986, 32:13-22.
99. Miller GJ Vitamin D and prostate cancer: Biologic interactions and clinical potentials. Cancer Metast Rev 1998, 17:353-360.
100. Polek TC, Weigel NL Vitamin D and prostate cancer. J Androl 2002, 23:9-17.
101. Leibowitz SB, Kantoff PW Differentiating agents and the treatment of prostate cancer: Vitamin D-3 and peroxisome proliferators-activated receptor gamma ligands. Sem Oncol 2003, 30:698-708.
102. Peehl DM, Krishnan AV, Feldman D Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003, 133:2461S-2469S.
103. Chen TC, Holick MR Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab 2003, 14:423-430.
104. 3 receptors and actions in human prostate cancer cell lines. Endocrinol 1993, 132(5):1952-1960.
105. 3 in the androgen-dependent LNCaP cells. Biochem and Biophys Res Comm 1996, 223:141-146.
106. Esquenet M, Swinned JV, Heyns W, Verhoeven G Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans-retinoic acid, 9-cis-retinoic acid, and phenylacetate. Prostate 1996, 28:182-194.
107. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR Human prostate cancer cell lines: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994, 14:1077-1081.
108. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995, 1:997-1003.
109. 3 on primary cultures of human prostatic cells. Cancer Res 1994, 54(3):805-810.
110. Schwartz GG, Wang M-H, Zhang M, Singh RK, Siegal GP 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiology, Biomarkers & Prevention 1997, 6:727-732.
111. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang S-H, Block NL, Binderup L Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiology, Biomarkers & Prevention 1999, 8:214-248.
112. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 2003, 164:273-288.
113. Poskitt EM, Cole TJ, Lawson DE Diet, sunlight, and 25-hydroxyvitamin D in healthy children and adults. Br Med J 1979, 1:221-223.
114. Chesney RW, Rosen JF, Hamstra AJ, Smith C, Mahaffey K, DeLuca HF Absence of seasonal variations in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J Clin Endocrin Metab 1981, 53:139-143.
115. Bell NH, Greene A, Epstein S, Oexman MH, Shaw S, Shary J Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985, 76:74-76.
116. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000, 6:901-908.
117. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidem Biomar 2000, 9:265-270.
118. 3. J Clin Invest 1976, 58:61-70.
119. Chen TC, Whitlatch LW, Young MV, Flanagan JN, Schwartz GG, Lokeshwar BL, Kong XF, Xue P, Holick MF Enhancement of 25-hydroxyvitamin D-1α-hydroxylase activity in prostate cells by gene transfection: A novel approach for the treatment of prostate cancer. Vitamin D Endocrine System: Structural, Biological, Genetic, and Clinical Aspects 2000, 525-528. University of California, Printing and Reprographics, Riverside CA. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
120. 3-induced growth inhibition. Cancer Res 2001, 61:2852-2856.
121. Wang L, Whitlatch LW, Flanagan JN, Holick MF, Chen TC Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res 2003, 164:223-237.
122. Wang L, Flanagan JN, Jamieson DP, Holick MF, Chen TC Regulation of 25-hydroxyvitamin D-1α-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol, in press.
123. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer and is enhanced by gene transfer. J Steroid Biochem Mol Biol 2002, 81:135-140.
124. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC The prostate 25-hydroxyvitamin D-1α-hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25:967-971.
125. Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994, 54:5579-5583.
126. Hsieh K, Albertsen PC Populations at high risk for prostate cancer. Urol Clin North Am 2003, 30:669-676.
127. Holick MF, Photobiology of vitamin D, In: Feldman D, Glorieux FH, Pike JW, Vitamin D, 1st ed, Academic Press: San Diego, CA: 33-39.
128. Wang L, Flanagan JN, Jamieson DP, Holick MF, Chen TC Regulation of 25-hydroxyvitamin D-1α-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol, in press.